|
Cancer Prevention Month: Protect your liver with
the world's first anti-cancer vaccine
| | |
Liver cancer cases are expected to grow dramatically over the next 20 years, but there is good news: it is highly preventable. Because chronic hepatitis B and C are primary risk factors, eliminating these infections is the most effective way to take a stand against liver cancer.
The hepatitis B vaccine is the world’s first “anti-cancer” vaccine. By preventing chronic hepatitis B infections, the vaccine directly prevents the development of liver cancer caused by the disease.
| | Share the Hepatitis B Foundation's Cancer Prevention Media Toolkit with your community. | |
-
Who should get vaccinated? The vaccine is recommended by U.S. policy for all infants, children and adults ages 19-59. Adults 60+ and those at high risk should also be vaccinated.
-
Global Impact: In many countries, vaccinating newborns at birth has already resulted in a dramatic reduction in new liver cancer cases.
| | |
| |
Learn more about staying protected:
Preventing chronic infection is also the most important way to prevent cirrhosis—a condition present in at least 80% of people diagnosed with liver cancer. While hepatitis B can sometimes lead to cancer without cirrhosis, staying proactive with vaccination and monitoring is your best defense.
| | | Featured #BtheVoice HCC storytellers in honor of World Cancer Day | |
In honor of World Cancer Day, Feb. 4, the Hepatitis B Foundation shared powerful, real-life stories of those living with liver cancer (HCC) from our #BtheVoice storytelling campaign. We stand with the millions of people affected by cancer worldwide.
Hearing from others is a vital part of finding hope, community and strength. We invite you to take a moment to listen to these voices and learn more about the impact of this disease.
| | | | | Learn more about liver cancer here. | | The Hepatitis B Foundation funds grassroots organizations in Africa | |
|
Out of more than 60 applications, these partners stood out for their commitment to eliminating hepatitis B through community leadership, equity and sustainable action.
Please join us in celebrating these community catalysts!
In launching ABAC, the Hepatitis B Foundation made a major, multi-year commitment to supporting hepatitis B elimination in Africa, where our staff have been working with partners in more than 12 countries. Please read the full list of grantees here.
| | | | Join us for the Annual Hepatitis B Foundation Gala | | |
Please join us for an inspiring evening at the Foundation's Annual Gala on April 10, 2026.
The 2026 Hepatitis B Foundation Gala is fast approaching, and we can’t wait to celebrate the remarkable progress we’ve made in expanding access to hep B testing, vaccination and treatment. This special evening will honor the strides taken to support individuals living with hepatitis B and advance global awareness.
🎫Learn more and reserve your tickets today: www.hepbgala.org
| | The Blumberg family speaks out about the hepatitis B birth dose | | | | |
In a recent meeting, a U.S. government committee voted to change a the long-standing recommendation for the universal hepatitis B birth dose vaccine. Since its inception, the birth dose has been a essential for global health—often called the "first anti-cancer vaccine" because it prevents the chronic infections that lead to liver cancer later in life.
Hepatitis B remains a leading cause of liver cancer worldwide. Because the virus can be transmitted from mother to child during birth—often without the mother knowing her status—the 24-hour window for the first vaccine dose is considered a critical period for protection.
| | The family of Dr. Baruch Blumberg, the man who discovered the virus and developed the first vaccine, released a statement expressing their deep concern: | "We are appalled by the decision of the CDC's vaccine advisory panel to officially recommend an alteration to the well-established protocols of the infant dose of the vaccine." | | Please read their full statement here. | | | |
Now available: 2025 updated hepatitis B
management guidance for primary care
| | |
We are eager to share the release of the updated 2025 Hepatitis B Management Guidance, a comprehensive resource specifically designed for primary care providers and non-specialists.
Developed by the HBV Primary Care Workgroup in collaboration with the University of Washington, this guidance simplifies hepatitis B management to support your clinical decision-making.
| | | |
The new guidance provides recommendations on:
- Prevention and diagnosis: Protocols for screening and identifying hepatitis B,
- Chronic management: Practical steps for long-term monitoring and care and
- HCC surveillance: Strategies for hepatocellular carcinoma [HCC] surveillance.
| | | |
Access the guidance in multiple formats:
| | Upcoming webinar: Navigating the updated AASLD hepatitis B guidelines | |
Please join us for an in-depth session on the updated 2025 AASLD hepatitis B guidelines.
The management of chronic hepatitis B is evolving rapidly. Staying current with the latest clinical guidance is essential for anyone working toward hepatitis B elimination and health equity. This webinar will provide a comprehensive overview of key changes and their direct implications for patient care.
| |
- Screening and monitoring
- Treatment eligibility
| |
- Special populations
- Practical application
| | | Whether you are a clinician, researcher, or advocate, this session will provide the clarity you need to understand what has changed and how it impacts your work. | | |
Thursday, Feb. 26, 2026 | 2 p.m. EST | | | | Share your voice on the Foundation's new quality of life survey | | | | |
The Hepatitis B Foundation is seeking participants for a new research study titled HepB PROACTive (Hepatitis B: Patient-Reported Outcomes, Adherence and Quality of Life Tracking).
The goal of this program is to better understand the daily experiences, treatment challenges and overall well-being of individuals living with chronic hepatitis B.
We're seeking adults age 18+ residing in the U.S., United Kingdom, Taiwan, Nigeria, Canada or Pakistan.
| | |
New B Informed Training Hub module:
Preventing mother-to-child transmission
| | | | |
FREE online hepatitis B training for all!
💡Learn about the importance of the hepatitis B birth dose vaccine and its critical role in preventing serious liver disease and liver cancer.
-
Explore strategies to implement the birth dose and the HBV vaccine series, and
- Download resources to educate your community.
Get started here.
| | The Foundation hosted the 2026 Hepatitis B Therapeutics Summit | | The Hepatitis B Foundation proudly hosted the 2026 Hepatitis B Therapeutics Summit in January, an event that brought together people living with hepatitis B and world-class researchers and industry leaders. | | | |
Throughout the summit, lived experience guided critical conversations on:
- Current and emerging hepatitis B treatment options,
- Advancements and ethics in clinical trials and
- Innovative therapeutic modalities on the horizon.
A special thank you to our sponsors for making this collaboration possible. Together, we advanced vital dialogue on risk tolerability and equity—ensuring that community insights are turned into actionable guidance for future drug development.
| | New B Heppy Podcast | Rav's story: Navigating life with hepatitis delta | | | | |
In this episode, Bright and Anousha speak with Ravshan Yakubov, a #justB storyteller and patient advocate living with hepatitis B and delta.
Diagnosed as a child in Uzbekistan, Rav later discovered he had hepatitis D and liver cirrhosis after moving to Canada. He shares his journey, the challenges of co-infection, and his hope for future treatment options.
| | |
Early detection is critical but difficult, as small tumors are easily missed on standard CT scans or MRIs. Artificial Intelligence (AI) is transforming this process by identifying patterns invisible to the human eye.
AI assist doctors with the detection and measurement of tumors, followed by identifying risks and treatment paths. It requires high-quality, diverse data to be accurate and many tools are still in the testing phase making it a challenge for doctors. Please read the full blog here.
| | | New translated hepatitis B birth dose fact sheets | | The Hepatitis B Foundation has created a Hep B Birth Dose Media Toolkit highlighting the life-saving impact of the HBV vaccine for communities, healthcare providers, and advocates. We are pleased to offer new and improved patient fact sheets in English, Spanish, Chinese and French. Download the PDFs today to raise awareness, encourage timely vaccination, and work towards a #HepBfree future for all children. | | Download this NEW hepatitis B app today for free | | |
Managing hepatitis B just got easier.
The HepB & Me app is designed to support individuals living with chronic hepatitis B and their health care professionals in navigating the best care possible.
- Track your health,
- Stay informed,
- Smart reminders and
- Partner with your provider.
| | | 2026 Baruch S. Blumberg Prize Seminar | | | | |
We invite you to join us on April 10, 2026 at 11 a.m. EST for the Virtual 2026 Baruch S. Blumberg Prize Seminar. We are honored to host the 2026 Blumberg Prize recipient, Fabien Zoulim, MD, PhD. The award will be presented at the Foundation's Annual Gala.
Dr. Zoulim will present: Advancing hepatitis B treatment towards a cure: A journey in hepatitis B research
Please register for the virtual event here.
| | Journal article of the month | | |
Insights from strengthening perinatal hepatitis B prevention in healthcare facilities in Delta State, Nigeria: A prospective, pilot implementation intervention.
Therapeutic Advances in Chronic Disease. 2026 Feb. 3; Volume 17 [LINK]
Okinedo P, Freeland C, Igumbor E, et al.
| | |
This study analyzed the effectiveness of Project StopHepB, which was then operating in five high-volume public health facilities in Delta State, Nigeria. Nearly 3,000 pregnant women were screened for hepatitis B and C. Among that population, the pooled prevalence of HBV infection was close to 2%, which was six times great than hepatitis C.
Prior to the project, because vaccination was not conducted daily in any of the facilities, the probability of any child receiving the hepatitis B vaccine, both newborns and older infants, on any day of the week including weekends, was 40%. The authors found that, "Post-intervention, this rose to 100% as all pilot facilities adopted daily vaccination practice."
The report concludes: "Project StopHepB interventions significantly improved early identification, linkage to care and timely HepB-BD vaccination, effectively closing gaps in HBV prevention of perinatal transmission. These findings support the scale-up of similar interventions to advance HBV elimination goals across other facilities in the state, in Nigeria, and to prevent new HBV infections in the future."
| |
- Virtual 2026 Blumberg Prize Seminar on April 10, 2026 at 11 a.m. EST - register here
- 2026 Annual Hepatitis B Foundation Gala - learn more
| |
|
The Hepatitis B Foundation is a global nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B. Our commitment includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families, the medical and scientific community and the general public.
Learn more about our research and education programs at www.hepb.org
| | | | | | | |